Brief: H Lundbeck Says Data Suggests MAB Potential Slowing Clinical Progression
05/03/2024 08:08
March 5 (Reuters) - H Lundbeck A/S HLUNb.CO :
* INITIAL CLINICAL DATA SUGGESTS THAT ANTI-ALPHA-SYNUCLEIN
MONOCLONAL ANTIBODY (MAB) HAS POTENTIAL TO SLOW CLINICAL
PROGRESSION
* PLANS TO INITIATE A PHASE III STUDY
* PRIMARY ENDPOINT SHOWED NON-STATISTICALLY SIGNIFICANT 19%
SLOWING OF CLINICAL PROGRESSION MEASURED BY UMSARS TOTAL SCORE
* LU AF82422 WAS GENERALLY WELL TOLERATED
Source text for Eikon: ID:nWkr9PVjXH
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options